Legal and Policy Issues Currently Facing the Industry
During these sessions, we will explore current legal and policy issues impacting the generic drug and biosimilar supply chain, including drug shortages and efforts in Congress to onshore production of critical drugs in the U.S. We will also review how health plan and PBM coverage and utilization management practices are impacting the sale of Humira biosimilars and future biosimilar competition. Finally, we will assess the impact of the interchangeability designation on U.S. biosimilar adoption and discuss how both federal and state policy and regulatory initiatives are impacting prescriber and pharmacy dispensing trends.
Legal and Policy
Who should attend:
Possible job titles include:
Regulatory Affairs, Medical Affairs, Business Development, Program Management, Policy, Commercial Development, Scientific Affairs, Research Analyst
About GRx+Biosims 2024
GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Get the latest information directly from Food and Drug Administration experts, understand the latest policy that impacts the industry and gain valuable insights to advance your professional development.
